Tarsus Pharmaceuticals (TARS) Insider Trading & Ownership $44.63 -0.20 (-0.45%) (As of 04:20 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.25%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$18,960.00Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$2.04 M Get TARS Insider Trade Alerts Want to know when executives and insiders are buying or selling Tarsus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TARS Insider Buying and Selling by Quarter Ad Wide Moat ResearchDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That’s why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?Get the full details now. Tarsus Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/18/2024Aziz MottiwalaInsiderSell4,766$30.60$145,839.60 3/18/2024Bobak R AzamianCEOSell10,415$30.60$318,699.00 3/18/2024Bryan WahlGeneral CounselSell4,436$30.60$135,741.60 3/18/2024Seshadri NeervannanCOOSell4,879$30.60$149,297.40 12/27/2023Bobak R AzamianCEOSell8,000$20.22$161,760.00 12/20/2023Bobak R AzamianCEOSell40,000$20.27$810,800.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/20/2023Jose M TrevejoInsiderSell2,252$20.00$45,040.00 12/15/2023Andrew D GoldbergDirectorBuy1,000$18.96$18,960.00 11/30/2023Bryan WahlGeneral CounselSell8,356$16.31$136,286.36 11/30/2023Dianne C WhitfieldInsiderSell8,355$16.31$136,270.05 (Data available from 1/1/2013 forward) TARS Insider Trading Activity - Frequently Asked Questions Who is on Tarsus Pharmaceuticals's Insider Roster? The list of insiders at Tarsus Pharmaceuticals includes Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Seshadri Neervannan, and Vivo Capital Ix, Llc. Learn more on insiders at TARS. What percentage of Tarsus Pharmaceuticals stock is owned by insiders? 8.25% of Tarsus Pharmaceuticals stock is owned by insiders. Learn more on TARS's insider holdings. Which Tarsus Pharmaceuticals insiders have been buying company stock? The following insiders have purchased TARS shares in the last 24 months: Andrew D Goldberg ($18,960.00), and Elizabeth Yeu Lin ($159,700.80). How much insider buying is happening at Tarsus Pharmaceuticals? Insiders have purchased a total of 10,506 TARS shares in the last 24 months for a total of $178,660.80 bought. Which Tarsus Pharmaceuticals insiders have been selling company stock? The following insiders have sold TARS shares in the last 24 months: Aziz Mottiwala ($235,840.83), Bobak R Azamian ($5,702,081.94), Bryan Wahl ($305,087.62), Dianne C Whitfield ($179,479.24), Jose M Trevejo ($87,281.86), Leonard M Greenstein ($295,902.33), Mark J Holdbrook ($5,008.19), and Seshadri Neervannan ($163,674.27). How much insider selling is happening at Tarsus Pharmaceuticals? Insiders have sold a total of 377,750 Tarsus Pharmaceuticals shares in the last 24 months for a total of $6,974,356.28 sold. Tarsus Pharmaceuticals Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanMr. Jeffrey S. Farrow (Age 62)CFO & Chief Strategy Officer Compensation: $722.95kDr. Seshadri Neervannan Ph.D. (Age 56)Chief Operating Officer Compensation: $759.2kDr. Elizabeth Yeu Lin M.D. (Age 46)Chief Medical Advisor & Director Compensation: $59.12kMr. David NakasoneHead of Investor RelationsDr. Bryan Wahl J.D. (Age 46)M.D., General Counsel & Corporate Secretary Compensation: $619.09kMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMs. Dianne C. Whitfield M.S.W. (Age 47)Chief Human Resources Officer Compensation: $578.9k More Insider Trading Tools from MarketBeat Related Companies Fusion Pharmaceuticals Insider Trades MeiraGTx Insider Trades Cytokinetics Insider Trades Blueprint Medicines Insider Trades Nuvalent Insider Trades Viking Therapeutics Insider Trades Lantheus Insider Trades Arcellx Insider Trades Crinetics Pharmaceuticals Insider Trades Avidity Biosciences Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:TARS) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | SponsoredA huge crack is forming in the US economyFormer Trump Advisor Warning: “An Economic Rupture Is Coming” The legendary financier Brad Thomas served on...Wide Moat Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
